Latest Research
All publications from the Cancer3.AI database, newest first.
Editorial: focus on the COMET trial.
Narod SA
A major clinical trial known as the COMET study examined whether immediate surgery is necessary for women diagnosed with ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer. The trial compared surgical intervention at the time of diagnosis against a watchful-waiting approach, tracking outcomes over two years. Remarkably, the study found that surgery did not reduce the subsequent incidence of invasive breast cancer compared to active monitoring alone. These findings challenge the longstanding assumption that DCIS reliably progresses to invasive cancer if left untreated. For patients and clinicians, this research opens the door to less aggressive management strategies for certain DCIS cases, potentially sparing many women from unnecessary surgery and its associated risks. The editorial underscores the need to fundamentally reconsider how we understand and treat early-stage breast cancer.
BJC reports
Source →Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.
Ye F, et al
Researchers used a powerful combination of spatial metabolomics and spatial transcriptomics to map the metabolic and genetic activity across different regions of bladder cancer tumors, revealing how tumor heterogeneity contributes to immune evasion. The study identified zinc finger protein 36 (ZFP36) as a key immunotherapeutic target, showing that high ZFP36 expression is strongly associated with worse patient outcomes in bladder cancer. Using genetically engineered mouse models in which ZFP36 was knocked out either throughout the whole body or specifically in T cells, the researchers demonstrated that removing ZFP36 lowers the activation threshold for T cells and increases their infiltration into tumors. Mechanistically, ZFP36 was found to degrade the messenger RNA of immune regulators such as C1QBP, thereby suppressing T cell activation and their ability to kill cancer cells. Crucially, combining ZFP36 knockout with anti-PD-1 immunotherapy produced synergistic antitumor effects in preclinical models, suggesting that targeting ZFP36 could significantly enhance the effectiveness of existing immunotherapies for bladder cancer patients.
Proceedings of the National Academy of Sciences of the United States of America
Source →Bleeding ileal conduit varices in a postoperative patient of urinary bladder carcinoma: percutaneous transhepatic variceal embolization to the rescue.
Sahoo B, et al
This case report describes a rare but serious complication in a man in his 50s who had previously undergone surgery for muscle-invasive bladder cancer, involving the formation of bleeding ectopic varices at the site of his ileal conduit — a surgically created urinary diversion using a segment of the small intestine. The patient experienced recurrent stomal hemorrhage, which prompted investigation and ultimately revealed the presence of atypical varices associated with liver cirrhosis. The medical team successfully treated the bleeding using percutaneous transhepatic glue embolization, a minimally invasive procedure in which a special adhesive agent is injected through the skin into the liver to seal off the abnormal blood vessels. The case highlights the importance of considering ectopic varices and underlying liver disease in bladder cancer patients who have undergone urinary diversion and present with unexplained stomal bleeding. Clinicians are reminded that selective embolization with coils or glue, as well as alternative techniques such as transjugular intrahepatic portosystemic shunt, represent effective management options for this uncommon condition.
BMJ case reports
Source →Clinical application of transurethral resection/electrocautery for urethral hemangiomas: two centers retrospective cohort study.
Huang J, et al
Researchers from two medical centers conducted a retrospective study to evaluate the safety and effectiveness of transurethral resection and electrocautery — a minimally invasive surgical technique — for treating urethral hemangiomas, which are rare benign blood vessel tumors of the urethra. The study included 42 patients treated between August 2018 and July 2025, making it the largest reported cohort of this condition worldwide. All surgeries were completed successfully with no intraoperative complications, a median operative time of just 10 minutes, and minimal blood loss, with only 12% of patients experiencing postoperative issues such as difficult urination or blood in the urine. During a median follow-up of 12 months, only one patient experienced tumor recurrence, and long-term complications including urethral stricture and urinary incontinence were noted in a small number of cases. These findings suggest that transurethral resection and electrocautery is a rapid, safe, and effective treatment option for urethral hemangiomas, offering clinicians a reliable minimally invasive approach for managing this rare condition.
Scandinavian journal of urology
Source →[Clear cell adenocarcinoma of the urinary tract: a clinicopathological analysis of nine cases].
Zeng WR, et al
Researchers at Sun Yat-sen Memorial Hospital conducted a retrospective study of nine patients diagnosed with clear cell adenocarcinoma (CCA) of the urinary tract, a rare and aggressive cancer, over nearly a decade. The study found that the disease predominantly affects middle-aged women, presenting with urinary irritation and blood in the urine, with tumors located in the urethra or bladder. Under the microscope, the tumors closely resembled ovarian clear cell adenocarcinoma, featuring papillary and tubular-cystic structures with clear or eosinophilic cells and high proliferative activity. Immunohistochemical testing revealed strong expression of PAX8, CK7, and HNF1-β markers, and the authors recommend using these alongside Napsin A as a core diagnostic panel, with SOX17 as an additional helpful marker. With a follow-up period of up to 58 months, two patients died and three experienced tumor recurrence, underscoring the malignant nature of this disease. These findings provide clinicians with clearer diagnostic criteria for a cancer that is easily confused with other urinary tract tumors, potentially improving patient outcomes through more accurate and timely diagnosis.
Zhonghua bing li xue za zhi = Chinese journal of pathology
Source →